Since the provided insights focus entirely on private companies (Science and Neuralink) and strategic startup takeaways rather than public market equities, there are no immediate stock tickers or public price targets available for investment. However, investors looking to gain exposure to the burgeoning brain-computer interface and medical device sectors should monitor public neurotechnology competitors like Blackrock Microsurgery or major medical device players such as Medtronic (MDT). Capital-intensive biotech and deep-tech firms focusing on commercialized medical devices with international approvals, similar to Science, offer strong long-term growth potential once they transition to public markets. Retail investors should prioritize companies in this space that demonstrate a clear path to profitability and reduced reliance on external fundraising rather than relying purely on speculative research.

Science (Private)

• The company focuses on brain-computer interfaces and its primary product is a retinal prosthesis chip implanted under the retina to restore vision to blind patients using a camera and laser projector.
• The retinal prosthesis has finished major clinical trials, been featured in the BBC, and is currently in clinical trials across six countries with an approved medical device in Europe.
• The company builds custom internal infrastructure software, such as an internal system called Helix, to handle purchasing, manufacturing attribution, hiring workflows, and continuous peer review tracking.
• The leadership emphasizes pushing for profitability and revenue generation alongside long-term research to reduce reliance on continuous external fundraising cycles.
• The company operates with a hybrid culture combining long-term transhumanist ambitions with practical, rigorous clinical and medical device execution.

Takeaways

• Startups operating in capital-intensive deep tech or biotech sectors should carefully calculate the actual cost of their core experiments and raise double that amount to account for unforeseen hurdles.
• Founders in complex industries should consider building custom internal software infrastructure to optimize operational speed, purchasing flow, and talent evaluation rather than relying strictly on generic off-the-shelf enterprise software.

Neuralink (Private)

• Max Hodak spent five years running the company, which served as a crucial environment for learning high-stakes decision-making and business judgment from experienced leadership.
• The experience highlighted the value of working within an established, high-performing company culture before launching a separate startup, as foundational startup principles and cultures are frequently passed down via oral traditions from previous companies.

Takeaways

• Aspiring entrepreneurs can benefit significantly from working at high-performing companies with strong cultures before starting their own ventures to refine their strategic decision-making filters.